Appendix 2—table 31. Antihypertensive Cohort (Region=New York State), Patient Characteristics Pre/Post Match.
| Region=NY by Antihypertensive Use: Unmatched | Region=NY by Antihypertensive Use: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | HTN Non-users | HTN Users | p-value | All | HTN Non-users | HTN Users | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 968,296 | 100.0% | 709,644 | 73.3% | 258,652 | 26.7% | 407,248 | 100.0% | 203,624 | 50.0% | 203,624 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 133,178 | 13.8% | 132,352 | 18.7% | 826 | 0.3% | <0.001 | 1,622 | 0.4% | 811 | 0.4% | 811 | 0.4% | 1.00 |
| 21-40 | 192,959 | 19.9% | 181,447 | 25.6% | 11,512 | 4.5% | 22,930 | 5.6% | 11,465 | 5.6% | 11,465 | 5.6% | ||
| 41-50 | 127,794 | 13.2% | 105,490 | 14.9% | 22,304 | 8.6% | 43,846 | 10.8% | 21,923 | 10.8% | 21,923 | 10.8% | ||
| 51-60 | 172,444 | 17.8% | 119,643 | 16.9% | 52,801 | 20.4% | 96,318 | 23.7% | 48,159 | 23.7% | 48,159 | 23.7% | ||
| 61-70 | 159,912 | 16.5% | 92,103 | 13.0% | 67,809 | 26.2% | 109,858 | 27.0% | 54,929 | 27.0% | 54,929 | 27.0% | ||
| 71-80 | 120,117 | 12.4% | 54,076 | 7.6% | 66,041 | 25.5% | 88,734 | 21.8% | 44,367 | 21.8% | 44,367 | 21.8% | ||
| ≥81 | 61,892 | 6.4% | 24,533 | 3.5% | 37,359 | 14.4% | 43,940 | 10.8% | 21,970 | 10.8% | 21,970 | 10.8% | ||
| Gender | ||||||||||||||
| Female | 573,610 | 59.2% | 419,901 | 59.2% | 153,709 | 59.4% | 0.02 | 240,930 | 59.2% | 120,465 | 59.2% | 120,465 | 59.2% | 1.00 |
| Male | 394,686 | 40.8% | 289,743 | 40.8% | 104,943 | 40.6% | 166,318 | 40.8% | 83,159 | 40.8% | 83,159 | 40.8% | ||
| Insurance | ||||||||||||||
| Commercial | 500,918 | 51.7% | 425,181 | 59.9% | 75,737 | 29.3% | <0.001 | 150,918 | 37.1% | 75,459 | 37.1% | 75,459 | 37.1% | 1.00 |
| Dual | 6,814 | 0.7% | 1,659 | 0.2% | 5,155 | 2.0% | 2,986 | 0.7% | 1,493 | 0.7% | 1,493 | 0.7% | ||
| Medicaid | 252,366 | 26.1% | 193,207 | 27.2% | 59,159 | 22.9% | 95,032 | 23.3% | 47,516 | 23.3% | 47,516 | 23.3% | ||
| Medicare | 208,198 | 21.5% | 89,597 | 12.6% | 118,601 | 45.9% | 158,312 | 38.9% | 79,156 | 38.9% | 79,156 | 38.9% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 521,282 | 53.8% | 423,952 | 59.7% | 97,330 | 37.6% | <0.001 | 181,234 | 44.5% | 90,617 | 44.5% | 90,617 | 44.5% | 1.00 |
| Yes | 447,014 | 46.2% | 285,692 | 40.3% | 161,322 | 62.4% | 226,014 | 55.5% | 113,007 | 55.5% | 113,007 | 55.5% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 0.65 | 1.39 | 0.46 | 1.16 | 1.17 | 1.80 | <0.001 | 0.95 | 1.60 | 0.95 | 1.60 | 0.95 | 1.60 | 1.00 |
CCI: Charlson Comorbidity Index; HTN: antihypertensive; PCP: primary care physician; SD: standard deviation.